Alembic Pharmaceuticals Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing an Alembic Pharmaceuticals target price for 2027 should start with where the stock sits today. At Rs 803.40 on 9 October 2026, it is 19.5% below its 52-week high of Rs 998.00 and 26.4% above its 52-week low of Rs 635.80. That range spans 57% from low to high, so the entry point matters as much as the Alembic Pharmaceuticals price forecast itself.

This article builds the Alembic Pharmaceuticals share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 838 base case and the Rs 1,019 bull case were reached, along with a downside risk level of Rs 641.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Stock Analysis: Company Overview and Key Stats

Alembic Pharmaceuticals (NSE: APLLTD) has a market capitalisation of Rs 15,733 crore. In FY26 it reported revenue of Rs 7,399 crore and net profit of Rs 670.83 crore. The table collects the figures the Alembic Pharmaceuticals share price target is built on.

Metric	Value
Company	Alembic Pharmaceuticals
NSE Ticker	APLLTD
CMP (9 October 2026)	Rs 803.40
52-Week High	Rs 998.00
52-Week Low	Rs 635.80
Market Cap	Rs 15,733 crore
PE Ratio (TTM)	22.82
Industry PE	37.59
Price to Book	2.77
Return on Equity	11.89%
Debt to Equity	0.25
EPS (TTM)	Rs 35.08
Dividend Yield	1.50%
12-Month Base Target	Rs 838
Bull Case	Rs 1,019
Downside Risk Level (not a target)	Rs 641

Why Is Alembic Pharmaceuticals Share Price Target Set at Rs 838 for 2027?

The base-case Alembic Pharmaceuticals stock target of Rs 838 applies a PE multiple of 22.82 to a forward EPS estimate of Rs 36.72. That EPS assumes 4.7% yearly growth, the pace from FY24 to FY26, and puts the target 4.3% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Alembic Pharmaceuticals Target Price: Five Years of Results

Alembic Pharmaceuticals grew revenue from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew more slowly, from Rs 520.94 crore to Rs 670.83 crore (6.5% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	5,356.25	520.94	26.50	10.00
FY23	5,655.36	341.99	17.40	8.00
FY24	6,256.93	615.82	31.33	11.00
FY25	6,714.63	582.01	29.68	11.00
FY26	7,399.31	670.83	34.33	12.00

FY26 revenue growth was 10.2%, close to the four-year average of 8.4%, and net profit moved up 15.3%. EPS rose from Rs 31.33 in FY24 to Rs 34.33 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Alembic Pharmaceuticals converted 9.1% of FY26 revenue into net profit, against 8.7% in FY25, within a five-year range of 6.0% to 9.8%. EBITDA margin was 14.9% in FY26 versus 15.9% in FY25.

In the June 2026 quarter, revenue was Rs 2,165 crore, up 26.1% from the same quarter a year earlier, while net profit of Rs 172.36 crore was up 12.2%. EBITDA came in at Rs 346.79 crore, up 20.5% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.25, and shareholders' equity grew from Rs 5,238 crore in FY22 to Rs 5,669 crore in FY26. Operating cash flow in FY26 was Rs 782.73 crore against capital expenditure of Rs 494.88 crore, leaving free cash flow of Rs 287.85 crore, or 1.8% of the current market capitalisation. In FY25 free cash flow was negative at Rs 475.66 crore, so cash generation has not been steady year to year.

Valuation Check for the Alembic Pharmaceuticals Stock Target: PE, Price to Book and ROE

At a PE of 22.82 against an industry PE of 37.59, Alembic Pharmaceuticals trades at a discount to its industry. Price to book is 2.77 on a book value of Rs 288.70 per share, and return on equity is 11.89%. A PE of 22.82 equals an earnings yield of 4.4%, and the FY26 dividend of Rs 12.00 per share gives a yield of 1.50%.

Shareholding Pattern and Institutional Holding

Promoters held 69.87% of Alembic Pharmaceuticals in June 2026, and promoter holding rose from 69.67% in June 2025 to 69.87% in June 2026. Foreign institutional investors (FII) held 4.18% and domestic institutions (DII) held 15.94%, which puts total institutional holding at 20.12%. FII holding rose from 3.96% in June 2025 to 4.18% in June 2026. Public shareholders own the remaining 10.01%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Alembic Pharmaceuticals Share Price Targets for the Short Term and 12 Months

Short Term Alembic Pharmaceuticals Stock Target Levels: Technical Setup

At Rs 803.40 on 9 October 2026, Alembic Pharmaceuticals trades below its 50-day simple moving average of Rs 825.07 and below its 200-day exponential moving average of Rs 816.38. The 14-day RSI reads 36.2, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 816.38 (200-day exponential moving average) and the nearest support is Rs 635.80 (52-week low). A sustained move above Rs 816.38 would improve the short-term setup, while a close below Rs 635.80 would shift attention to the next support.

12 Month Alembic Pharmaceuticals Target Price for 2027

The 12-month target for Alembic Pharmaceuticals is Rs 838: forward EPS of Rs 36.72 at a PE of 22.82. That is 4.3% above Rs 803.40. It would still leave the stock 16.0% below its 52-week high of Rs 998.00. The upside in the base case is thin, so the thesis here leans on the bull case and on patience.

How EPS Growth and PE Multiple Change the Alembic Pharmaceuticals Target Price

EPS Growth	PE 18.26	PE 22.82	PE 26.24
0.0% (EPS Rs 35.08)	Rs 641	Rs 801	Rs 920
4.7% (EPS Rs 36.72)	Rs 671	Rs 838	Rs 964
10.7% (EPS Rs 38.83)	Rs 709	Rs 886	Rs 1,019

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Alembic Pharmaceuticals price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Alembic Pharmaceuticals Stock Target in 2027

Bull Case Rs 1,019

The bull case Alembic Pharmaceuticals price target needs EPS growth of 10.7%, which lifts forward EPS to Rs 38.83, and a PE multiple that rises 15% to 26.24. That gives Rs 1,019, 26.8% above the current price and above the 52-week high of Rs 998.00, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 641

The downside risk level is not a target. It assumes EPS stays flat at Rs 35.08 and the PE falls 20% to 18.26. That gives Rs 641, 20.2% below the current price and above the 52-week low of Rs 635.80.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	10.7%	26.24	Rs 1,019	+26.8%
Base Case	4.7%	22.82	Rs 838	+4.3%
Downside Risk	0.0%	18.26	Rs 641	-20.2%

Key Risks to the Alembic Pharmaceuticals Target Price for 2027

Growth Slowdown Risk for the Alembic Pharmaceuticals Price Target

Revenue in the June 2026 quarter was up 26.1% year on year, and FY26 revenue growth was 10.2%. If growth slows from here, the EPS estimate behind the Alembic Pharmaceuticals stock target will need revising.

Liquidity and Size Risk

Alembic Pharmaceuticals has a market capitalisation of Rs 15,733 crore. Institutional holding is 20.12%, and promoters hold 69.87%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 9.1% in FY26, so a small slip in costs moves profit noticeably. At a PE of 22.82 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 18.26 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 19.5% below its 52-week high, with an RSI of 36.2 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Alembic Pharmaceuticals

Start with the live price and volume. Any Alembic Pharmaceuticals share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 803.40 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Alembic Pharmaceuticals' PE, ROE, debt and shareholding in one place.

Check Alembic Pharmaceuticals fundamentals on the Univest Screener

Then compare the three Alembic Pharmaceuticals target price scenarios with your own view. If you expect EPS growth below 4.7%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals live price and get daily stock recommendations.

Conclusion

The Alembic Pharmaceuticals share price target for 2027 is Rs 838 in the base case, with Rs 1,019 as the bull case. The support for that view is arithmetic you can check: EPS grew 4.7% a year over FY24 to FY26, and the stock trades at a PE of 22.82. The risks are equally concrete, including a stock that sits 19.5% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Alembic Pharmaceuticals Share Price Target 2027

What is the Alembic Pharmaceuticals share price target for 2027?

Ans. The base-case Alembic Pharmaceuticals share price target for 2027 is Rs 838, with Rs 1,019 as the bull case. The downside risk level, which is not a target, is Rs 641. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Alembic Pharmaceuticals share price today?

Ans. As of 9 October 2026, 12:52 PM IST, Alembic Pharmaceuticals trades at Rs 803.40, up 0.36% on the day. The 52-week range is Rs 635.80 to Rs 998.00.

Is Alembic Pharmaceuticals a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 4.7% a year over FY24 to FY26, but the stock is 19.5% below its 52-week high. Whether Alembic Pharmaceuticals fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Alembic Pharmaceuticals shares?

Ans. The bull case target is Rs 1,019, which assumes 10.7% EPS growth and a PE of 26.24. The downside risk level is Rs 641, which assumes flat EPS and a PE of 18.26. It marks a risk, not a target.

What are the main risks to the Alembic Pharmaceuticals price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 15,733 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Alembic Pharmaceuticals and how does it compare with the industry?

Ans. The PE ratio of Alembic Pharmaceuticals is 22.82 against an industry PE of 37.59. Price to book is 2.77 and return on equity is 11.89%. The base case in the Alembic Pharmaceuticals price target holds this PE constant.

Who owns Alembic Pharmaceuticals, and what is the promoter holding?

Ans. Promoters held 69.87% of Alembic Pharmaceuticals in June 2026. FII held 4.18%, DII held 15.94% and the public held 10.01%.

What were Alembic Pharmaceuticals' latest quarterly results?

Ans. In the June 2026 quarter, Alembic Pharmaceuticals reported revenue of Rs 2,165 crore (up 26.1% year on year) and net profit of Rs 172.36 crore (up 12.2%).